Penn Medicine Provider
Hematology
Michael R. Cook, MD
5.0
(238)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Penn Presbyterian
View 1 additional location
Make an appointmentCall 215-662-9801

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Temple University School of Medicine
  • Residency: Georgetown University Medical Center
  • Fellowship: Georgetown University Medical Center

What my patients think about me

Average Rating
5.0

238 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
she asked me everything as if she was a doctor her self.
April 2025
5.0
5.0
excellent. effortlessly patient, answered all my questions to my satisfaction and complete understanding. wonderful person & excellent doctor. i feel lucky & blessed to have dr. michael cook as my provider. thank you!
April 2025
5.0
5.0
his approach of recommending needed treatment but not over treating.
April 2025
5.0
5.0
always professional and explains everything in detail. very thorough

Insurance accepted

My Locations

Learn about location
Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Cook is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Nikita K. Dave, Veronica Carvajal, Alex C. Watts, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei-Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma , Blood Neoplasia: 2025

Cook, M.R. Williams, L. Kolm, P. Dunleavy, K. Improved Survival Outcomes for Intensive versus Standard Chemoimmunotherapy in Primary Mediastinal B-cell Lymphoma: A Meta-Analysis of 4068 Patients. , Haematologica, 109(3): 2024

Cook, M.R, Shouval, R. Perales, M, et al. Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL). , ASH Annual Conference 2023: 2023

Cook, M.R. Dorris, SC. Makambi, K. Luo, Y. Munshi, P. Donato, M. Rowley, S. Saad, A. Goy, A. Dunleavy, K. Ali, A. Toxicity and Efficacy of Chimeric Antigen Receptor (CAR) T-cell Therapy in Primary and Secondary CNS Lymphoma: A Meta-Analysis of 128 Patients. , Blood Adv , 7(1): 2023,32-39

Shah NJ, Cook MR, Wu T, Lev-Ari SL, Blackburn MB, Serzan MT, Alaoui A, Atkins, MB. Association Between Immune Checkpoint Inhibitors, Corticosteroids, Immunosuppressive Agents and Opportunistic Infections. , Journal of the National Comprehensive Cancer Network, 20(7): 2022

Shah NJ, Cook MR, Wu T, Lev-Ari SL, Blackburn MB, Serzan MT, Alaoui A, Atkins, MB. The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids , J Natl Compr Canc Netw , 20(7): 2022,800-807.e1.

Cook, M.R. Dunleavy, K. Targeting the Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic strategies. , Current Oncology Reports, 24: 2022,1121-1131

Zhang D, Shah NJ, Cook MR, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins MB, Braithwaite D. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. , Cancers (Basel) , 13(23): 2021,6109

Cook, M., Dykes, K., White, K., Desale, S., Agrawal, R., Fernandez, S., Huang, X., Cobb, N., Lai, C. Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19. , Clinical Lymphoma, Myeloma & Leukemia: 2021

Cook, M.R. Karp, J.E. Lai, C. The Spectrum of Genetic Mutations in Myelodysplastic Syndrome: Should We Update Prognostication? , EJHaem , 3(1): 2021,301-313